AllSci News
FibroBiologics secures up to USD 9.0m in PIPE funds to extend runway
Houston-based FibroBiologics, Inc. (Nasdaq: FBLG) announced the closing of a private placement on June 29, 2026, raising USD 3.0 million in upfront gross...
Pyxis secures USD 114m to push MICVO toward dual clinical readouts in head and neck cancer
Boston-based Pyxis Oncology, Inc. (Nasdaq: PYXS) announced a private placement of up to USD 114 million to extend its cash runway into Q2 2027 and fund two...
Cogent advances bezuclastinib toward approval across three mastocytosis indications simultaneously
Cogent Biosciences (Nasdaq: COGT) has submitted its third New Drug Application to the US FDA in six months, filing for bezuclastinib in advanced systemic...
Moleculin's annamycin delivers three-fold remission advantage in relapsed AML interim analysis
Moleculin Biotech (Nasdaq: MBRX) reported that annamycin (naxtarubicin), its liposomal anthracycline candidate, produced complete remission rates roughly...
Abivax reports additional Phase III maintenance data supporting obefazimod in ulcerative colitis
Abivax (Nasdaq: ABVX) reported Phase III ABTECT maintenance results for obefazimod in moderately to severely active ulcerative colitis that demonstrated...
Abivax raises USD 600m to fuel US launch of obefazimod ahead of NDA submission
France-based Abivax SA (Euronext Paris: ABVX / Nasdaq: ABVX) announced the launch of an underwritten public offering of approximately USD 600 million (EUR...
Hanmi completes USD 41m-backed acquisition of Aptose, securing tuspetinib AML program
South Korea-based Hanmi Pharmaceutical Co., Ltd. has completed its acquisition of Aptose Biosciences Inc. (TSX: APS | OTC: APTOF), a clinical-stage oncology...
Mesoblast advances first cellular therapy for life-threatening LVAD complications
Australia-based Mesoblast Limited (ASX: MSB; Nasdaq: MESO) has received a Biologics License Application filing number from the US FDA and requested a...
Nicox's NCX 470 advances to FDA review as first nitric oxide-donating glaucoma therapy
Kowa Company, Ltd.'s submission of a New Drug Application (NDA) to the US FDA for NCX 470 (bimatoprost grenod), developed by France-based Nicox SA (Paris:...
Ipsen to acquire Memo Therapeutics for EUR 700m to gain first-in-class BK virus antibody
France-based Ipsen (Euronext: IPN; ADR: IPSEY) has agreed to acquire Switzerland-based Memo Therapeutics AG in a deal totaling more than EUR 700 million,...
UCSF engineers ALPPL2-targeted bispecific TCE aiming for solid cancers
University of California, San Francisco has received a USD 1.64 million National Cancer Institute R01 award to develop a bispecific T cell engager targeting...
Vistagen's fasedienol fails second Phase III social anxiety trial, clouding acute treatment strategy
Vistagen Therapeutics (Nasdaq: VTGN) reported that its PALISADE-4 Phase III trial of fasedienol for social anxiety disorder failed to meet its primary...
FDA issues second CRL to Unicycive’s oxylanthanum for CKD over manufacturing deficiencies
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) received a second Complete Response Letter from the US FDA for the resubmitted New Drug Application for…
Feinstein Institutes secures NIH funding for inflammation and Alzheimer's disease research
Feinstein Institutes for Medical Research has received USD 4.9 million in NIH grants across two multi-year awards targeting acute inflammation and...
FDA’s manufacturing concerns stall Galderma’s US entry for Relfydess neuromodulator
Switzerland-based Galderma (SIX: GALD) disclosed that the US FDA has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA)…
The AllSci Brief
Free, systematic R&D and deal news. Daily.